Search Results for “Shire ” – Page 6 – media

New IVF technique hailed as the ‘most exciting advance in fertility treatment for 40 years’

A new IVF method that takes thousands of pictures of embryos to select the best eggs has increased the likelihood of a baby being born by 25 percent.
- Source: Daily Mail
- 503
- January 15, 2018
IVF pregnancy Researches
Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS

Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
- Source: Prnewswire
- 448
- January 9, 2018
ALS FTLD Market Views neurodegenerative disease
Scholar Rock scoops $47M to trial SMA drug

Scholar Rock has raised $47 million to take its treatment for spinal muscular atrophy (SMA) into the clinic. The series C tees up Scholar Rock to find out whether its myostatin blocker can best the underwhelming performance of one-time rivals from companies including Novartis.
- Source: fiercebiotech
- 494
- January 4, 2018
blocker Company Insight myostatin SMA
New Formulation of ONCASPAR®▼ (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced that the European Commission (EC) granted Marketing Authorization for lyophilized ONCASPAR (pegaspargase), as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL) in pediatric patients from birth to 18 years, and in adult patients.1 The approval – which authorizes Shire to market lyophilized ONCASPAR in the 28 member states of the European Union (EU), as well as Iceland, Liechtenstein and Norway – follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12.
- Source: Shire
- 608
- December 15, 2017
ALL Antineoplastic New Approvals
First Video Game Therapy Heads to FDA As Akili Touts ADHD Study Win

For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
- Source: xconomy
- 490
- December 7, 2017
ADHD Attention Performance Index Company Insight video game
metaLinear Secures 255K Pound Seed Investment for Targeted Antibacterial Research

MetaLinear is a start-up biotechnology company founded in 2017, focused on the identification and validation of new drug targets for difficult to treat bacterial infections. The new investment was secured from the BioCity Group Ltd, who manage the Alderley Park Ventures (APV) fund and Catapult Ventures, who manage the Greater Manchester and Cheshire (GM&C) Life Sciences Fund. Both funds look to back innovative, high-technology companies providing much needed early stage finance.
- Source: biocity.co.uk;
- 476
- December 1, 2017
bacterial infections Market Views new drug
FDA OKs Genentech’s Gazyva for Untreated Follicular Lymphoma

Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
- Source: Biospace
- 595
- November 21, 2017
cancer FDA hemophilia lymphoma New Approvals
Flu Vax May Improve Outcomes in Other Illnesses

Even when the flu vaccine doesn't prevent disease, it can ease some of the consequences, researchers said here.
- Source: medpagetoday
- 835
- November 2, 2017
disease flu Researches vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.